Sinovac gets a shot in the arm
US law firm O’Melveny & Myers represented UBS Securities and Piper Jaffray as joint book-running managers in the US$66 million follow-on public offering of NASDAQ-listed Sinovac Biotech in February
Volume 1, Issue 3
Subscribers can sign in to access the following PDF.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.
Highlights:
US law firm O’Melveny & Myers represented UBS Securities and Piper Jaffray as joint book-running managers in the US$66 million follow-on public offering of NASDAQ-listed Sinovac Biotech in February
Join our mailing list for legal news and alerts
Sign up